Koyfin Home > Directory > Health Care > Amag Pharmaceuticals > Long-Term Debt / Capital

Amag Pharmaceuticals Long-Term Debt / Capital Chart (AMAG)

Amag Pharmaceuticals annual/quarterly Long-Term Debt / Capital from 2014 to 2020.
  • Amag Pharmaceuticals Long-Term Debt / Capital for the quarter ending June 06, 2020 was $55m a 33.51% increase of 18m year over year
  • Amag Pharmaceuticals Long-Term Debt / Capital for the last 12 months ending June 06, 2020 was $55m a 33.51% increase of 18m year over year
  • Amag Pharmaceuticals Annual Long-Term Debt / Capital for 2019 was $51m a 49.99% increase of 26m from 2018
  • Amag Pharmaceuticals Annual Long-Term Debt / Capital for 2018 was $26m a -88.49% decrease of -23m from 2017
  • Amag Pharmaceuticals Annual Long-Term Debt / Capital for 2017 was $48m a -4.31% decrease of -2m from 2016
Other Ratios Metrics:
  • Amag Pharmaceuticals Total Debt / Capital for the quarter ending September 09, 2018 was $27m a -79.63% decrease of -21m year over year
  • Amag Pharmaceuticals Other Liabilities for the quarter ending December 12, 2018 was $1m a -3,223.97% decrease of -46m year over year
  • Amag Pharmaceuticals Total Debt / Equity for the quarter ending September 09, 2018 was $37m a -153.66% decrease of -56m year over year
View Chart On Koyfin

Quarterly AMAG Long-Term Debt / Capital Data

06/2020$55m
03/2020$53m
12/2019$51m
09/2019$36m
06/2019$35m
03/2019$30m
12/2018$26m
09/2018$25m
06/2018$49m
03/2018$49m

Annual AMAG Long-Term Debt / Capital Data

2019$51m
2018$26m
2017$48m
2016$50m
2015$51m
2014$48m